Engineered immune cells take on Hard-to-Treat liver tumors
NCT ID NCT06515314
First seen Dec 11, 2025 · Last updated May 23, 2026 · Updated 28 times
Summary
This early-phase trial tests a new treatment called HRYZ-T102, which uses a patient's own immune cells that are specially trained to attack cancer cells that make a protein called AFP. The study includes up to 12 adults with advanced liver cancer or other solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose, while also watching for signs of tumor shrinkage or control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital Affiliated to Fudan University
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.